Yann Mazabraud to Resign as Chief Commercial Officer and Head of International from Trevi Therapeutics, Inc., Effective October 3, 2020
September 11, 2020 at 09:14 pm
Share
On September 8, 2020, Yann Mazabraud notified Trevi Therapeutics, Inc. of his intention to resign from his position as Chief Commercial Officer and Head of International of the Company, effective October 3, 2020.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Companyâs Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Companyâs subsidiary is Trevi Therapeutics Limited.